

Xiaofeng Zeng

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2147883/publications.pdf>

Version: 2024-02-01

265
papers

5,217
citations

159585

30
h-index

138484

58
g-index

289
all docs

289
docs citations

289
times ranked

7515
citing authors

#	ARTICLE	IF	CITATIONS
1	The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China. <i>Clinical Immunology</i> , 2020, 214, 108393.	3.2	1,031
2	Performance improvement of perovskite solar cells by employing a CdSe quantum dot/PCBM composite as an electron transport layer. <i>Journal of Materials Chemistry A</i> , 2017, 5, 17499-17505.	10.3	293
3	Clinical characteristics of immunoglobulin G4-related disease: a prospective study of 118 Chinese patients. <i>Rheumatology</i> , 2015, 54, 1982-1990.	1.9	185
4	Aberrant Expansion and Function of Follicular Helper T Cell Subsets in IgG4-Related Disease. <i>Arthritis and Rheumatology</i> , 2018, 70, 1853-1865.	5.6	89
5	The role of gut microbiota in the pathogenesis of rheumatic diseases. <i>Clinical Rheumatology</i> , 2018, 37, 25-34.	2.2	83
6	JAK Inhibitors: Prospects in Connective Tissue Diseases. <i>Clinical Reviews in Allergy and Immunology</i> , 2020, 59, 334-351.	6.5	83
7	Clinical characteristics and survival of pulmonary arterial hypertension associated with three major connective tissue diseases: A cohort study in China. <i>International Journal of Cardiology</i> , 2017, 236, 432-437.	1.7	81
8	Guidelines for the diagnosis and treatment of osteoarthritis in China (2019 edition). <i>Annals of Translational Medicine</i> , 2020, 8, 1213-1213.	1.7	73
9	Chinese Registry of rheumatoid arthritis (CREDIT): II. Prevalence and risk factors of major comorbidities in Chinese patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2017, 19, 251.	3.5	68
10	Synovitis, acne, pustulosis, hyperostosis and osteitis syndrome: a single centre study of a cohort of 164 patients. <i>Rheumatology</i> , 2016, 55, 1023-1030.	1.9	67
11	Baseline Characteristics and Risk Factors of Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus Patients. <i>Medicine (United States)</i> , 2016, 95, e2761.	1.0	59
12	Failure of remission induction by glucocorticoids alone or in combination with immunosuppressive agents in IgG4-related disease: a prospective study of 215 patients. <i>Arthritis Research and Therapy</i> , 2018, 20, 65.	3.5	58
13	Diagnostic value of anti-cyclic citrullinated Peptide antibody in patients with rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2003, 30, 1451-5.	2.0	55
14	Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 724-726.	0.9	51
15	Remission rate and predictors of remission in patients with rheumatoid arthritis under treat-to-target strategy in real-world studies: a systematic review and meta-analysis. <i>Clinical Rheumatology</i> , 2019, 38, 727-738.	2.2	50
16	A pilot study of tofacitinib for refractory Behçet's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1517-1520.	0.9	50
17	High TLR7 Expression Drives the Expansion of CD19+CD24hiCD38hi Transitional B Cells and Autoantibody Production in SLE Patients. <i>Frontiers in Immunology</i> , 2019, 10, 1243.	4.8	49
18	Long-term prognosis of patients with systemic lupus erythematosus-associated pulmonary arterial hypertension: CSTAR-PAH cohort study. <i>European Respiratory Journal</i> , 2019, 53, 1800081.	6.7	49

#	ARTICLE	IF	CITATIONS
19	Anti-Cyclic Citrullinated Peptide Antibody Is Associated with Interstitial Lung Disease in Patients with Rheumatoid Arthritis. <i>PLoS ONE</i> , 2014, 9, e92449.	2.5	47
20	NLRP12 autoinflammatory disease: a Chinese case series and literature review. <i>Clinical Rheumatology</i> , 2017, 36, 1661-1667.	2.2	46
21	Survival and prognostic factors of systemic lupus erythematosus-associated pulmonary arterial hypertension: A PRISMA-compliant systematic review and meta-analysis. <i>Autoimmunity Reviews</i> , 2016, 15, 250-257.	5.8	45
22	High levels of circulating cell-free DNA are a biomarker of active SLE. <i>European Journal of Clinical Investigation</i> , 2018, 48, e13015.	3.4	45
23	Successful treatment of arthritis and rash with tofacitinib in systemic lupus erythematosus: the experience from a single centre. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1441-1443.	0.9	43
24	The clinical characteristics of Chinese Takayasu's arteritis patients: a retrospective study of 411 patients over 24 years. <i>Arthritis Research and Therapy</i> , 2017, 19, 107.	3.5	41
25	Chinese SLE Treatment and Research Group Registry: III. Association of Autoantibodies with Clinical Manifestations in Chinese Patients with Systemic Lupus Erythematosus. <i>Journal of Immunology Research</i> , 2014, 2014, 1-8.	2.2	40
26	Presence of Anti-MDA5 Antibody and Its Value for the Clinical Assessment in Patients With COVID-19: A Retrospective Cohort Study. <i>Frontiers in Immunology</i> , 2021, 12, 791348.	4.8	39
27	Relationship between disease activity, organ damage and health-related quality of life in patients with systemic lupus erythematosus: A systemic review and meta-analysis. <i>Autoimmunity Reviews</i> , 2021, 20, 102691.	5.8	38
28	Cerebral venous sinus thrombosis in Behçet's disease: a retrospective case-control study. <i>Clinical Rheumatology</i> , 2018, 37, 51-57.	2.2	36
29	Malignancy and IgG4-related disease: the incidence, related factors and prognosis from a prospective cohort study in China. <i>Scientific Reports</i> , 2020, 10, 4910.	3.3	36
30	IgG4-related aortitis/periaortitis and periarteritis: a distinct spectrum of IgG4-related disease. <i>Arthritis Research and Therapy</i> , 2020, 22, 103.	3.5	35
31	Hospitalization mortality and associated risk factors in patients with polymyositis and dermatomyositis: A retrospective case-control study. <i>PLoS ONE</i> , 2018, 13, e0192491.	2.5	35
32	Single-cell analyses highlight the proinflammatory contribution of C1q-high monocytes to Behçet's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	7.1	35
33	Anti-Endothelin Receptor Type A Autoantibodies in Systemic Lupus Erythematosus-Associated Pulmonary Arterial Hypertension. <i>Arthritis and Rheumatology</i> , 2015, 67, 2394-2402.	5.6	34
34	Prognostic profile of systemic sclerosis: analysis of the clinical EUSTAR cohort in China. <i>Arthritis Research and Therapy</i> , 2018, 20, 235.	3.5	32
35	Assessment of anti-MDA5 antibody as a diagnostic biomarker in patients with dermatomyositis-associated interstitial lung disease or rapidly progressive interstitial lung disease. <i>Oncotarget</i> , 2017, 8, 76129-76140.	1.8	31
36	Clinical Characteristics of Heart Involvement in Chinese Patients with Takayasu Arteritis. <i>Journal of Rheumatology</i> , 2017, 44, 1867-1874.	2.0	30

#	ARTICLE	IF	CITATIONS
37	Myositis-specific autoantibodies in dermatomyositis/polymyositis with interstitial lung disease. <i>Journal of the Neurological Sciences</i> , 2019, 397, 123-128.	0.6	28
38	Tofacitinib for the Treatment of Nail Lesions and Palmoplantar Pustulosis in Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis Syndrome. <i>JAMA Dermatology</i> , 2021, 157, 74.	4.1	28
39	Tocilizumab for refractory rapidly progressive interstitial lung disease related to anti-MDA5-positive dermatomyositis. <i>Rheumatology</i> , 2021, 60, e227-e228.	1.9	28
40	Pulmonary arterial hypertension associated with primary Sjögren's syndrome: a multicentre cohort study from China. <i>European Respiratory Journal</i> , 2020, 56, 1902157.	6.7	27
41	Pulmonary arterial hypertension in systemic lupus erythematosus based on a CSTAR-PAH study: Baseline characteristics and risk factors. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 921-928.	1.9	26
42	Tofacitinib in patients with refractory Takayasu's arteritis. <i>Rheumatology</i> , 2020, 59, e95-e98.	1.9	26
43	The PD-1/PD-L pathway in rheumatic diseases. <i>Journal of the Formosan Medical Association</i> , 2021, 120, 48-59.	1.7	26
44	Prevalence, severity, and clinical features of acute and chronic pancreatitis in patients with systemic lupus erythematosus. <i>Rheumatology International</i> , 2016, 36, 1413-1419.	3.0	25
45	Efficacy between high and medium doses of glucocorticoid therapy in remission induction of IgG4-related diseases: a preliminary randomized controlled trial. <i>International Journal of Rheumatic Diseases</i> , 2017, 20, 639-646.	1.9	25
46	Primary Sjögren's syndrome is associated with increased risk of malignancies besides lymphoma: A systematic review and meta-analysis. <i>Autoimmunity Reviews</i> , 2022, 21, 103084.	5.8	25
47	Pregnancy in polymyositis or dermatomyositis: retrospective results from a tertiary centre in China. <i>Rheumatology</i> , 2017, 56, 1272-1275.	1.9	24
48	The renal artery is involved in Chinese Takayasu's arteritis patients. <i>Kidney International</i> , 2018, 93, 245-251.	5.2	24
49	2020 Chinese guidelines for the diagnosis and treatment of systemic lupus erythematosus. <i>Rheumatology and Immunology Research</i> , 2020, 1, 5-23.	0.8	24
50	Intracardiac thrombus in patients with Behcet's disease: clinical correlates, imaging features, and outcome: a retrospective, single-center experience. <i>Clinical Rheumatology</i> , 2016, 35, 2501-2507.	2.2	23
51	Different patterns of cerebral perfusion in SLE patients with and without neuropsychiatric manifestations. <i>Human Brain Mapping</i> , 2020, 41, 755-766.	3.6	23
52	Clinical efficacy and safety of sirolimus in systemic lupus erythematosus: a real-world study and meta-analysis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2020, 12, 1759720X2095333.	2.7	23
53	Clinical Features, Morbidity, and Risk Factors of Intestinal Pseudo-obstruction in Systemic Lupus Erythematosus: A Retrospective Case-control Study. <i>Journal of Rheumatology</i> , 2016, 43, 559-564.	2.0	22
54	Systemic lupus erythematosus-associated diffuse alveolar hemorrhage: a single-center, matched case-control study in China. <i>Lupus</i> , 2020, 29, 795-803.	1.6	22

#	ARTICLE	IF	CITATIONS
55	Predictive value of non-invasive right ventricle to pulmonary circulation coupling in systemic lupus erythematosus patients with pulmonary arterial hypertension. <i>European Heart Journal Cardiovascular Imaging</i> , 2021, 22, 111-118.	1.2	22
56	The five major autoimmune diseases increase the risk of cancer: epidemiological data from a large-scale cohort study in China. <i>Cancer Communications</i> , 2022, 42, 435-446.	9.2	22
57	Chinese Systemic Lupus Erythematosus Treatment and Research Group Registry VI: Effect of Cigarette Smoking on the Clinical Phenotype of Chinese Patients with Systemic Lupus Erythematosus. <i>PLoS ONE</i> , 2015, 10, e0134451.	2.5	21
58	Characteristics and risk factors of pulmonary arterial hypertension in patients with primary Sjögren's syndrome. <i>International Journal of Rheumatic Diseases</i> , 2018, 21, 1068-1075.	1.9	21
59	Serum KL-6 is associated with the severity of interstitial lung disease in Chinese patients with polymyositis and dermatomyositis. <i>Clinical Rheumatology</i> , 2019, 38, 2181-2187.	2.2	21
60	Care for patients with rheumatic diseases during COVID-19 pandemic: A position statement from APLAR. <i>International Journal of Rheumatic Diseases</i> , 2020, 23, 717-722.	1.9	21
61	Comparison of the Efficacy and Safety of Adalimumab (Humira) and the Adalimumab Biosimilar Candidate (HS016) in Chinese Patients with Active Ankylosing Spondylitis: A Multicenter, Randomized, Double-Blind, Parallel, Phase III Clinical Trial. <i>BioDrugs</i> , 2020, 34, 381-393.	4.6	21
62	CRDC: a Chinese rheumatology research platform. <i>Clinical Rheumatology</i> , 2015, 34, 1347-1352.	2.2	20
63	The efficacy of Mycophenolate mofetil for the treatment of Chinese Takayasu's arteritis. <i>Scientific Reports</i> , 2016, 6, 38687.	3.3	20
64	Tofacitinib as a possible treatment for skin thickening in diffuse cutaneous systemic sclerosis. <i>Rheumatology</i> , 2021, 60, 2472-2477.	1.9	20
65	Chinese registry of rheumatoid arthritis (CREDIT): I. Introduction and prevalence of remission in Chinese patients with rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 836-840.	0.8	20
66	Red blood cell distribution width as a related factor of pulmonary arterial hypertension in patients with systemic sclerosis. <i>Clinical Rheumatology</i> , 2018, 37, 979-985.	2.2	19
67	Phenotypes and genotypes of Chinese adult patients with systemic autoinflammatory diseases. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 49, 446-452.	3.4	19
68	Clinical characteristics and risk factors for overlapping rheumatoid arthritis and Sjögren's syndrome. <i>Scientific Reports</i> , 2018, 8, 6180.	3.3	18
69	Malignancy development risk in psoriatic arthritis patients undergoing treatment: A systematic review and meta-analysis. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 626-631.	3.4	18
70	Differences and similarities between IgG4-related disease with and without dacryoadenitis and sialoadenitis: clinical manifestations and treatment efficacy. <i>Arthritis Research and Therapy</i> , 2019, 21, 44.	3.5	18
71	Serum IgE in the clinical features and disease outcomes of IgG4-related disease: a large retrospective cohort study. <i>Arthritis Research and Therapy</i> , 2020, 22, 255.	3.5	18
72	Prognosis of adult idiopathic inflammatory myopathy-associated interstitial lung disease: a retrospective study of 679 adult cases. <i>Rheumatology</i> , 2021, 60, 1195-1204.	1.9	18

#	ARTICLE	IF	CITATIONS
73	Predicting the Risk of Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus: A Chinese Systemic Lupus Erythematosus Treatment and Research Group Cohort Study. <i>Arthritis and Rheumatology</i> , 2021, 73, 1847-1855.	5.6	18
74	Efficacy and safety of iguratimod plus corticosteroid as bridge therapy in treating mild IgG4-related diseases: A prospective clinical trial. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 1479-1488.	1.9	17
75	Takayasu Arteritis With Coronary Artery Involvement: Differences Between Pediatric and Adult Patients. <i>Canadian Journal of Cardiology</i> , 2020, 36, 535-542.	1.7	17
76	Rheumatic immune-related adverse events induced by immune checkpoint inhibitors. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021, 17, 178-185.	1.1	17
77	Hierarchical cluster analysis of cytokine profiles reveals a cutaneous vasculitis-associated subgroup in dermatomyositis. <i>Clinical Rheumatology</i> , 2021, 40, 999-1008.	2.2	17
78	Multimodal photoacoustic/ultrasonic imaging system: a promising imaging method for the evaluation of disease activity in rheumatoid arthritis. <i>European Radiology</i> , 2021, 31, 3542-3552.	4.5	17
79	Antibodies against glycoprotein 2 display diagnostic advantages over ASCA in distinguishing CD from intestinal tuberculosis and intestinal Behçet's disease. <i>Clinical and Translational Gastroenterology</i> , 2018, 9, e133.	2.5	16
80	Differences in clinical characteristics of IgG4-related disease across age groups: a prospective study of 737 patients. <i>Rheumatology</i> , 2021, 60, 2635-2646.	1.9	16
81	Association between acute phase reactants, interleukin-6, tumor necrosis factor- α , and disease activity in Takayasu's arteritis patients. <i>Arthritis Research and Therapy</i> , 2020, 22, 285.	3.5	16
82	Changes of Serum IgG Glycosylation Patterns in Primary Biliary Cholangitis Patients. <i>Frontiers in Immunology</i> , 2021, 12, 669137.	4.8	16
83	Antibodies to phosphatidylserine/prothrombin (aPS/PT) enhanced the diagnostic performance in Chinese patients with antiphospholipid syndrome. <i>Clinical Chemistry and Laboratory Medicine</i> , 2018, 56, 939-946.	2.3	15
84	Sirolimus for patients with connective tissue disease-related refractory thrombocytopenia: a single-arm, open-label clinical trial. <i>Rheumatology</i> , 2021, 60, 2629-2634.	1.9	15
85	Efficacy and safety of nintedanib in Asian patients with systemic sclerosis-associated interstitial lung disease: Subgroup analysis of the SENSICIS trial. <i>Respiratory Investigation</i> , 2021, 59, 252-259.	1.8	15
86	The LPS induced pyroptosis exacerbates BMP2 signaling deficiency to potentiate SLE-PAH. <i>FASEB Journal</i> , 2021, 35, e22044.	0.5	15
87	Correlation of Th17 cells and CD4 ⁺ CD25 ⁺ regulatory T cells with clinical parameters in patients with systemic sclerosis. <i>Chinese Medical Journal</i> , 2014, 127, 3557-61.	2.3	15
88	The Clinical Features, Risk Factors, and Outcome of Aneurysmal Lesions in Behçet's Disease. <i>Journal of Immunology Research</i> , 2019, 2019, 1-8.	2.2	14
89	MicroRNA-320a: an important regulator in the fibrotic process in interstitial lung disease of systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2021, 23, 21.	3.5	14
90	Related factors of fetal loss in Chinese women with systemic lupus erythematosus: data from Chinese SLE Treatment and Research Group registry IV. <i>International Journal of Rheumatic Diseases</i> , 2015, 18, 654-660.	1.9	13

#	ARTICLE	IF	CITATIONS
91	Upregulation of CD16 ⁺ monocyte subsets in systemic lupus erythematosus patients. <i>Clinical Rheumatology</i> , 2017, 36, 2281-2287.	2.2	13
92	Chinese SLE Treatment and Research Group (CSTAR) registry:VIII. Influence of socioeconomic and geographical variables on disease phenotype and activity in Chinese patients with <sc>SLE</sc>. <i>International Journal of Rheumatic Diseases</i> , 2018, 21, 716-724.	1.9	13
93	Quantitative T2 mapping accelerated by GRAPPATINI for evaluation of muscles in patients with myositis. <i>British Journal of Radiology</i> , 2019, 92, 20190109.	2.2	13
94	Evaluation of a commercial immunoassay for autoantibodies in Chinese Han systemic sclerosis population. <i>Clinica Chimica Acta</i> , 2019, 491, 121-125.	1.1	13
95	Autoimmune disease-associated non-Hodgkin ⁺ lymphoma ⁺ a large retrospective study from China. <i>Annals of Hematology</i> , 2019, 98, 445-455.	1.8	13
96	Comparison of Clinical Features in HLA-B27 Positive and Negative Patients With Axial Spondyloarthritis: Results From a Cohort of 4,131 Patients. <i>Frontiers in Medicine</i> , 2020, 7, 609562.	2.6	13
97	Association between comorbidities and extraglandular manifestations in primary Sj ⁺ gren ⁺ syndrome: a multicenter cross-sectional study. <i>Clinical Rheumatology</i> , 2020, 39, 2677-2688.	2.2	13
98	Identifying clinical subgroups in IgG4-related disease patients using cluster analysis and IgG4-RD composite score. <i>Arthritis Research and Therapy</i> , 2020, 22, 7.	3.5	13
99	Comparative diagnostic efficacy of serum Krebs von den Lungen-6 and surfactant D for connective tissue disease-associated interstitial lung diseases. <i>Medicine (United States)</i> , 2020, 99, e19695.	1.0	13
100	Bone mineral density and microarchitecture among Chinese patients with rheumatoid arthritis: a cross-sectional study with HRpQCT. <i>Arthritis Research and Therapy</i> , 2021, 23, 127.	3.5	13
101	Plasma-Derived Exosomal hsa-miR-4488 and hsa-miR-1228-5p: Novel Biomarkers for Dermatomyositis-Associated Interstitial Lung Disease with Anti-Melanoma Differentiation-Associated Protein 5 Antibody-Positive Subset. <i>BioMed Research International</i> , 2021, 2021, 1-16.	1.9	13
102	The efficacy of tocilizumab for the treatment of Chinese Takayasu's arteritis. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 103, 171-175.	0.8	13
103	Metabolomic alterations associated with Beh ⁺ et ⁺ disease. <i>Arthritis Research and Therapy</i> , 2018, 20, 214.	3.5	12
104	Effectiveness and safety of interferon β 2a as an add-on treatment for refractory Beh ⁺ et ⁺ uveitis. <i>Therapeutic Advances in Chronic Disease</i> , 2019, 10, 204062231984788.	2.5	12
105	Clinical Characteristics of Peripheral Neuropathy in Eosinophilic Granulomatosis with Polyangiitis: A Retrospective Single-Center Study in China. <i>Journal of Immunology Research</i> , 2020, 2020, 1-10.	2.2	12
106	Cardiac Involvement in Eosinophilic Granulomatosis With Polyangiitis: A Retrospective Study in the Chinese Population. <i>Frontiers in Medicine</i> , 2020, 7, 583944.	2.6	12
107	Rheumatic immune-related adverse events associated with immune checkpoint inhibitors compared with placebo in oncologic patients: a systemic review and meta-analysis. <i>Therapeutic Advances in Chronic Disease</i> , 2021, 12, 204062232097699.	2.5	12
108	Anti-inflammatory and immune therapy in severe coronavirus disease 2019 (COVID-19) patients: An update. <i>Clinical Immunology</i> , 2022, 239, 109022.	3.2	12

#	ARTICLE	IF	CITATIONS
109	High-throughput sequencing of CD4+ T cell repertoire reveals disease-specific signatures in IgG4-related disease. <i>Arthritis Research and Therapy</i> , 2019, 21, 295.	3.5	11
110	Urinary System Manifestation of IgG4-Related Disease: Clinical, Laboratory, Radiological, and Pathological Spectra of a Chinese Single-Centre Study. <i>Journal of Immunology Research</i> , 2020, 2020, 1-10.	2.2	11
111	Comparative efficacy of traditional non-selective NSAIDs and selective cyclo-oxygenase-2 inhibitors in patients with acute gout: a systematic review and meta-analysis. <i>BMJ Open</i> , 2020, 10, e036748.	1.9	11
112	Assessment of lung glucose uptake in patients with systemic lupus erythematosus pulmonary arterial hypertension: a quantitative FDG-PET imaging study. <i>Annals of Nuclear Medicine</i> , 2020, 34, 407-414.	2.2	11
113	Aberrant monocyte subsets in patients with Behçet's disease. <i>Clinical Immunology</i> , 2021, 225, 108683.	3.2	11
114	Three new inflammatory markers C reactive protein to albumin ratio, neutrophil to lymphocyte ratio, and platelet to lymphocyte ratio correlated with relapsing polychondritis disease activity index. <i>Clinical Rheumatology</i> , 2021, 40, 4685-4691.	2.2	11
115	Reversible posterior leukoencephalopathy syndrome secondary to systemic-onset juvenile idiopathic arthritis: A case report and review of the literature. <i>Biomedical Reports</i> , 2015, 3, 55-58.	2.0	10
116	Anti-SmD1 antibodies are associated with renal disorder, seizures, and pulmonary arterial hypertension in Chinese patients with active SLE. <i>Scientific Reports</i> , 2017, 7, 7617.	3.3	10
117	Red blood cell distribution width as a potential predictor of survival of pulmonary arterial hypertension associated with primary Sjogren's syndrome: a retrospective cohort study. <i>Clinical Rheumatology</i> , 2019, 38, 477-485.	2.2	10
118	Inflammation in SLE-PAH: good news or not?. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, e135-e135.	0.9	10
119	Decision-making value of nuclear dense fine speckled pattern in systemic autoimmune rheumatic disease: trick or treat?. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, e92-e92.	0.9	10
120	Comparison of the Effects of Cyclophosphamide and Mycophenolate Mofetil Treatment Against Immunoglobulin G4-Related Disease: A Retrospective Cohort Study. <i>Frontiers in Medicine</i> , 2020, 7, 253.	2.6	10
121	Clinical Features and Outcomes of Neuropsychiatric Systemic Lupus Erythematosus in China. <i>Journal of Immunology Research</i> , 2021, 2021, 1-10.	2.2	10
122	Activation of Toll-Like Receptor 7 Signaling Pathway in Primary Sjogren's Syndrome-Associated Thrombocytopenia. <i>Frontiers in Immunology</i> , 2021, 12, 637659.	4.8	10
123	Chinese SLE Treatment and Research group (CSTAR) registry 2009-2019: Major clinical characteristics of Chinese patients with systemic lupus erythematosus. <i>Rheumatology and Immunology Research</i> , 2021, 2, 43-47.	0.8	10
124	Clinical characteristics and outcome of IgG4-related disease with hypocomplementemia: a prospective cohort study. <i>Arthritis Research and Therapy</i> , 2021, 23, 102.	3.5	10
125	Myocardial involvement in idiopathic inflammatory myopathies: a multi-center cross-sectional study in the CRDC-MYO Registry. <i>Clinical Rheumatology</i> , 2021, 40, 4597-4608.	2.2	10
126	Evaluation of the Diagnostic Value of Non-criteria Antibodies for Antiphospholipid Syndrome Patients in a Chinese Cohort. <i>Frontiers in Immunology</i> , 2021, 12, 741369.	4.8	10

#	ARTICLE	IF	CITATIONS
127	Programmed Cell Death Pathways in the Pathogenesis of Idiopathic Inflammatory Myopathies. <i>Frontiers in Immunology</i> , 2021, 12, 783616.	4.8	10
128	Prevalence and risk factors of active tuberculosis in patients with rheumatic diseases: a multi-center, cross-sectional study in China. <i>Emerging Microbes and Infections</i> , 2021, 10, 2303-2312.	6.5	10
129	Establishment of a serum IgG4 cut-off value for the differential diagnosis of IgG4-related disease in Chinese population. <i>Modern Rheumatology</i> , 2016, 26, 583-587.	1.8	9
130	Flares in Chinese systemic lupus erythematosus patients: a 6-year follow-up study. <i>Clinical Rheumatology</i> , 2017, 36, 2727-2732.	2.2	9
131	Influence of Cigarette Smoking on Rheumatoid Arthritis Risk in the Han Chinese Population. <i>Frontiers in Medicine</i> , 2017, 4, 76.	2.6	9
132	CD146: a potential therapeutic target for systemic sclerosis. <i>Protein and Cell</i> , 2018, 9, 1050-1054.	11.0	9
133	Right Ventricular Function is Associated With Quality of Life in Patients With Systemic Lupus Erythematosus Associated Pulmonary Arterial Hypertension. <i>Heart Lung and Circulation</i> , 2019, 28, 1655-1663.	0.4	9
134	Imbalance of the CD226/TIGIT Immune Checkpoint Is Involved in the Pathogenesis of Primary Biliary Cholangitis. <i>Frontiers in Immunology</i> , 2020, 11, 1619.	4.8	9
135	Immunoglobulin A Isotype of Antiphospholipid Antibodies Does Not Provide Added Value for the Diagnosis of Antiphospholipid Syndrome in a Chinese Population. <i>Frontiers in Immunology</i> , 2020, 11, 568503.	4.8	9
136	<i>Tripterygium wilfordii</i> Hook F. in the treatment of synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome: a clinical trial. <i>Clinical Rheumatology</i> , 2021, 40, 2427-2438.	2.2	9
137	2018 Chinese guidelines for the diagnosis and treatment of rheumatoid arthritis. <i>Rheumatology and Immunology Research</i> , 2021, 2, 1-14.	0.8	9
138	Comparison of Different Test Systems for the Detection of Antiphospholipid Antibodies in a Chinese Cohort. <i>Frontiers in Immunology</i> , 2021, 12, 648881.	4.8	9
139	Comparison of relapsing polychondritis patients with and without central nervous system involvement: A retrospective study of 181 patients. <i>International Journal of Immunopathology and Pharmacology</i> , 2021, 35, 205873842110005.	2.1	9
140	The Role of Anti-U1 RNP Positivity in Predicting Survival in Patients With Connective Tissue Disease-Associated Pulmonary Arterial Hypertension: Angel or Demon? Comment on the Article by Sobanski et al. <i>Arthritis and Rheumatology</i> , 2016, 68, 1788-1789.	5.6	8
141	The Clinical Features and Risk Factors of Parenchymal Neuro-Behçet's Disease. <i>Journal of Immunology Research</i> , 2019, 2019, 1-7.	2.2	8
142	The Chinese herb <i>Tripterygium wilfordii</i> Hook F for the treatment of systemic sclerosis-associated interstitial lung disease: data from a Chinese EUSTAR Center. <i>Clinical Rheumatology</i> , 2020, 39, 813-821.	2.2	8
143	Predictive Value of Pulmonary Arterial Compliance in Systemic Lupus Erythematosus Patients With Pulmonary Arterial Hypertension. <i>Hypertension</i> , 2020, 76, 1161-1168.	2.7	8
144	Clinical manifestations of Behçet's disease in a large cohort of Chinese patients: gender- and age-related differences. <i>Clinical Rheumatology</i> , 2020, 39, 3449-3454.	2.2	8

#	ARTICLE	IF	CITATIONS
145	<p>Satisfaction of Patients and Physicians with Treatments for Rheumatoid Arthritis: A Population-Based Survey in China</p>. Patient Preference and Adherence, 2020, Volume 14, 1037-1047.	1.8	8
146	Clinical features of central nervous system involvement in patients with eosinophilic granulomatosis with polyangiitis: a retrospective cohort study in China. Orphanet Journal of Rare Diseases, 2021, 16, 152.	2.7	8
147	The current status and challenges in the diagnosis and treatment of rheumatoid arthritis in China: An annual report of 2019. Rheumatology and Immunology Research, 2021, 2, 49-56.	0.8	8
148	Risk of osteonecrosis in systemic lupus erythematosus: An 11-year Chinese single-center cohort study. Lupus, 2021, 30, 1459-1468.	1.6	8
149	Characteristics and Outcomes of Coronary Artery Involvement in Polyarteritis Nodosa. Canadian Journal of Cardiology, 2021, 37, 895-903.	1.7	8
150	Upadacitinib in patients from China, Brazil, and South Korea with rheumatoid arthritis and an inadequate response to conventional therapy. International Journal of Rheumatic Diseases, 2021, 24, 1530-1539.	1.9	8
151	Sirolimus versus tacrolimus for systemic lupus erythematosus treatment: results from a real-world CSTAR cohort study. Lupus Science and Medicine, 2022, 9, e000617.	2.7	8
152	Pituitary Involvement in Granulomatosis with Polyangiitis: A Retrospective Analysis in a Single Chinese Hospital and a Literature Review. International Journal of Endocrinology, 2019, 2019, 1-9.	1.5	7
153	Prevalence, predictors and prognostic benefits of remission achievement in patients with systemic lupus erythematosus: a systematic review. Arthritis Care and Research, 2020, , .	3.4	7
154	Successful treatment of refractory thrombotic thrombocytopenic purpura associated with systemic lupus erythematosus with combination of plasma exchange and low-dose rituximab. Lupus, 2020, 29, 1961-1967.	1.6	7
155	Analysis of myositis autoantibodies in Chinese patients with cancer-associated myositis. Journal of Clinical Laboratory Analysis, 2020, 34, e23307.	2.1	7
156	Musculoskeletal ultrasound imaging training, use, and knowledge among rheumatologists in China. Clinical Rheumatology, 2021, 40, 321-330.	2.2	7
157	Iguratimod treatment reduces disease activity in early primary Sjögren's syndrome: An open-label pilot study. Modern Rheumatology, 2021, 31, 394-398.	1.8	7
158	Peripheral B-Cell Immunophenotyping Identifies Heterogeneity in IgG4-Related Disease. Frontiers in Immunology, 2021, 12, 747076.	4.8	7
159	The 2013 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Systemic Sclerosis Could Classify Systemic Sclerosis Patients at Earlier Stage: Data from a Chinese EUSTAR Center. PLoS ONE, 2016, 11, e0166629.	2.5	7
160	Co-expression network analysis reveals the pivotal role of mitochondrial dysfunction and interferon signature in juvenile dermatomyositis. PeerJ, 2020, 8, e8611.	2.0	7
161	Long-term outcomes of patients with systemic lupus erythematosus: A Multicenter Cohort Study from CSTAR registry. Rheumatology and Immunology Research, 2021, 2, 195-202.	0.8	7
162	Predictors of health-related quality of life in patients with systemic lupus erythematosus associated pulmonary arterial hypertension. Clinical and Experimental Rheumatology, 2016, 34, 291-5.	0.8	7

#	ARTICLE	IF	CITATIONS
163	Aberrant glycosylation in autoimmune disease. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 767-775.	0.8	7
164	The treatment strategy of connective tissue disease associated pulmonary arterial hypertension: Evolving into the future. , 2022, 239, 108192.		7
165	Diagnostic value of the interferon- β release assay for tuberculosis infection in patients with Behçet's disease. <i>BMC Infectious Diseases</i> , 2019, 19, 323.	2.9	6
166	Can low-dose methotrexate reduce effusion-synovitis and symptoms in patients with mid- to late-stage knee osteoarthritis? Study protocol for a randomised, double-blind, and placebo-controlled trial. <i>Trials</i> , 2020, 21, 795.	1.6	6
167	Prevalence and Associated Factors of Lupus in the United States: Third National Health and Nutritional Examination Survey (NHANES III). <i>Frontiers in Medicine</i> , 2020, 7, 213.	2.6	6
168	Proteomic analyses of plasma-derived exosomes in immunoglobulin (Ig) G4-related disease and their potential roles in B cell differentiation and tissue damage. <i>Journal of Autoimmunity</i> , 2021, 122, 102650.	6.5	6
169	Tonsillitis as a possible predisposition to synovitis, acne, pustulosis, hyperostosis and osteitis (SAPHO) syndrome. <i>International Journal of Rheumatic Diseases</i> , 2021, 24, 519-525.	1.9	6
170	Using the co-expression network of T cell-activation-related genes to assess the disease activity in Takayasu's arteritis patients. <i>Arthritis Research and Therapy</i> , 2021, 23, 303.	3.5	6
171	Is it possible to apply the treat-to-target strategy in primary Sjögren's syndrome-associated pulmonary arterial hypertension?. <i>Clinical Rheumatology</i> , 2018, 37, 2989-2998.	2.2	5
172	Identification of 6 dermatomyositis subgroups using principal component analysis-based cluster analysis. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 1383-1392.	1.9	5
173	Factors Associated With Renal Involvement in Primary Sjögren's Syndrome: A Meta-Analysis. <i>Frontiers in Medicine</i> , 2020, 7, 614482.	2.6	5
174	Clinical Characteristics of Systemic Lupus Erythematosus with Cirrhosis. <i>Journal of Immunology Research</i> , 2020, 2020, 1-7.	2.2	5
175	Clinical characteristics and prognosis of concomitant systemic lupus erythematosus and primary biliary cholangitis. <i>Clinical Rheumatology</i> , 2021, 40, 1819-1826.	2.2	5
176	The role of PD-1/PD-Ls in the pathogenesis of IgG4-related disease. <i>Rheumatology</i> , 2022, 61, 815-825.	1.9	5
177	Clinical features and treatment efficacy for IgG4-related thyroiditis. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 324.	2.7	5
178	Cardiac manifestations of eosinophilic granulomatosis with polyangiitis from a single-center cohort in China: clinical features and associated factors. <i>Therapeutic Advances in Chronic Disease</i> , 2021, 12, 204062232098705.	2.5	5
179	Reduction in SLEDAI is associated with improved arterial stiffness in systemic lupus erythematosus. <i>Medicine (United States)</i> , 2020, 99, e23184.	1.0	5
180	Cysteine-rich protein 61 as a novel biomarker in systemic lupus erythematosus-associated pulmonary arterial hypertension. <i>Clinical and Experimental Rheumatology</i> , 2019, 37, 623-632.	0.8	5

#	ARTICLE	IF	CITATIONS
181	Clinical features of immunoglobulin G4-related disease with central nervous system involvement: an analysis of 15 cases. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 626-632.	0.8	5
182	Clinical characteristics of axial spondyloarthritis patients in China: results from ChinaSpA, the Chinese Spondyloarthritis Registry. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 544-550.	0.8	5
183	Pregnancy outcomes in Takayasu arteritis patients. <i>Seminars in Arthritis and Rheumatism</i> , 2022, 55, 152016.	3.4	5
184	Familial Mediterranean fever in Chinese adult patients. <i>Rheumatology</i> , 2018, 57, 2140-2144.	1.9	4
185	Baseline high-sensitivity C-reactive protein predicts the risk of incident ankylosing spondylitis: Results of a community-based prospective study. <i>PLoS ONE</i> , 2019, 14, e0211946.	2.5	4
186	Assessing the Quality of Global Clinical Practice Guidelines on Gout Using AGREE II Instrument. <i>Journal of Clinical Rheumatology</i> , 2020, 26, 54-59.	0.9	4
187	Plasticity of Treg and imbalance of Treg/Th17 cells in patients with systemic sclerosis modified by FK506. <i>International Journal of Immunopathology and Pharmacology</i> , 2021, 35, 205873842199808.	2.1	4
188	Prevalence and risk factors for left ventricular diastolic dysfunction in systemic sclerosis: a multi-center study of CRDC cohort in China. <i>Clinical Rheumatology</i> , 2021, 40, 4589-4596.	2.2	4
189	UPLC-MS based plasma metabolomics and lipidomics reveal alterations associated with IgG4-related disease. <i>Rheumatology</i> , 2021, 60, 3252-3261.	1.9	4
190	Expanded CD4+CXCR5-PD-1+ peripheral T helper like cells and clinical significance in IgG4-related disease. <i>Clinical Immunology</i> , 2022, 237, 108975.	3.2	4
191	Single-Cell Characterization of Hepatic CD8+ T Cells in a Murine Model of Primary Biliary Cholangitis. <i>Frontiers in Immunology</i> , 2022, 13, 860311.	4.8	4
192	A retrospective study of joint infections in patients with systemic lupus erythematosus. <i>Clinical Rheumatology</i> , 2017, 36, 2011-2017.	2.2	3
193	Chinese registry of rheumatoid arthritis (CREDIT): III. The transition of disease activity during follow-up and predictors of achieving treatment target. <i>International Journal of Rheumatic Diseases</i> , 2020, 23, 1719-1727.	1.9	3
194	Clinical features and long-term outcomes of Chinese patients with scleroderma renal crisis. <i>International Journal of Rheumatic Diseases</i> , 2020, 23, 1194-1200.	1.9	3
195	Aberrant expression of cell-free nucleosomes in dermatomyositis/polymyositis. <i>Dermatologic Therapy</i> , 2020, 33, e14460.	1.7	3
196	Development and formulation of the classification criteria for osteoarthritis. <i>Annals of Translational Medicine</i> , 2020, 8, 1068-1068.	1.7	3
197	Prolonged-Release (PR) Oxycodone/Naloxone Improves Bowel Function Compared with Oxycodone PR and Provides Effective Analgesia in Chinese Patients with Non-malignant Pain: A Randomized, Double-Blind Trial. <i>Advances in Therapy</i> , 2020, 37, 1188-1202.	2.9	3
198	Renal Involvement and HBV Infection Are Common in Chinese Patients With Cryoglobulinemia. <i>Frontiers in Immunology</i> , 2021, 12, 580271.	4.8	3

#	ARTICLE	IF	CITATIONS
199	Validation of the REVEAL Prognostic Models in Systemic Lupus Erythematosus-Associated Pulmonary Arterial Hypertension. <i>Frontiers in Medicine</i> , 2021, 8, 618486.	2.6	3
200	Ultra-microangiography in evaluating the disease activity of rheumatoid arthritis and enhancing the efficacy of ultrasonography: A preliminary study. <i>European Journal of Radiology</i> , 2021, 137, 109567.	2.6	3
201	Esophagus involvement in systemic sclerosis: ultrasound parameters and association with clinical manifestations. <i>Arthritis Research and Therapy</i> , 2021, 23, 122.	3.5	3
202	Interventricular systolic asynchrony predicts prognosis in patients with systemic sclerosis-associated pulmonary arterial hypertension. <i>Rheumatology</i> , 2021, , .	1.9	3
203	Phenotype, function and clinical significance of innate lymphoid cells in immunoglobulin G4-related disease. <i>Rheumatology</i> , 2022, 61, 2197-2209.	1.9	3
204	Clinical Characteristics and Prognoses of Patients With Systemic Lupus Erythematosus Hospitalized for Pulmonary Infections. <i>Frontiers in Medicine</i> , 2021, 8, 732681.	2.6	3
205	First China Approved Rituximab Biosimilar HLX01: Pharmacokinetics, Safety and Efficacy Comparison to Reference Rituximab in the Phase 3 Diffuse Large B-Cell Lymphoma Study. <i>Blood</i> , 2019, 134, 2878-2878.	1.4	3
206	The role of anti-ribosomal P autoantibodies in the prediction of neuropsychiatric damage in systemic lupus erythematosus based on CSTAR cohort (XIV). <i>Clinical Rheumatology</i> , 2022, 41, 1371-1379.	2.2	3
207	Detection of IgA Antiphospholipid Antibodies Does not Improve Thrombotic Antiphospholipid Syndrome Classification: A two-Center Study. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2022, 28, 107602962210811.	1.7	3
208	Prediction of new organ onset in recurrent immunoglobulin G4-related disease during 10 years of follow-up. <i>Journal of Internal Medicine</i> , 2022, 292, 91-102.	6.0	3
209	Prognostic factors of systemic lupus erythematosus patients with pulmonary embolism: An 11-year cohort study. <i>Lupus</i> , 2022, 31, 885-890.	1.6	3
210	Treatment and follow-up of 18 severe systemic lupus erythematosus patients with stem cell transplantation. <i>APLAR Journal of Rheumatology</i> , 2006, 9, 49-55.	0.2	2
211	SAT0139: A MULTICENTRE, RANDOMISED, DOUBLE-BLIND, PARALLEL ACTIVE-CONTROLLED CLINICAL TRIAL COMPARING PHARMACOKINETICS, PHARMACODYNAMICS, SAFETY AND EXPLORATORY EFFICACY BETWEEN HLX01 AND EUROPE-SOURCED RITUXIMAB AS A NEW INDICATION IN CHINESE MODERATE TO SEVERE PATIENTS WITH RHEUMATOID ARTHRITIS. . 2019. . . .		2
212	Changes in Efficacy Indicators for Adalimumab Biosimilar Candidate (HS016) for the Treatment of Active Ankylosing Spondylitis at Various Time Points. <i>Frontiers in Pharmacology</i> , 2020, 11, 606497.	3.5	2
213	A modified regimen of low-dose rituximab therapy for patients with refractory immune thrombocytopenia associated with systemic lupus erythematosus. <i>Therapeutic Advances in Chronic Disease</i> , 2021, 12, 204062232110486.	2.5	2
214	Evaluation of adalimumab biosimilar candidate (HS016) in Chinese patients with active ankylosing spondylitis based on a health survey: sub-analysis of a phase 3 study. <i>Clinical Rheumatology</i> , 2022, 41, 731-739.	2.2	2
215	Characteristics and long-term outcomes of patients with lupus-related protein-losing enteropathy: A retrospective study. <i>Rheumatology and Immunology Research</i> , 2020, 1, 47-52.	0.8	2
216	Characteristics and risk factors of pulmonary embolism in patients with systemic lupus erythematosus: a case control study. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 940-948.	0.8	2

#	ARTICLE	IF	CITATIONS
217	Recommendations in clinical practice guidelines on gout: systematic review and consistency analysis. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 964-972.	0.8	2
218	IgG4-related fibrosing mediastinitis: clinical presentation, treatment efficacy and comparison with IgG4-RD without fibrosing mediastinitis. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 1206-1214.	0.8	2
219	Persistent enlargement of the pancreatic gland after glucocorticoid therapy increases the risk of relapse in IgG4-related autoimmune pancreatitis. <i>Clinical Rheumatology</i> , 2022, , 1.	2.2	2
220	Impact of pregnancy in patients with systemic lupus erythematosus-associated pulmonary arterial hypertension: case series and literature review. <i>Lupus Science and Medicine</i> , 2022, 9, e000636.	2.7	2
221	The challenges and future perspective for the management of systemic lupus erythematosus in China: A concise annual report of 2020. <i>Rheumatology and Immunology Research</i> , 2022, 3, 38-44.	0.8	2
222	Secukinumab in the treatment of parenchymal neuro-Behçet's syndrome. <i>Rheumatology</i> , 2022, 61, e277-e279.	1.9	2
223	Exploring the risk factors and prognosis of transverse myelitis in systemic lupus erythematosus. <i>Therapeutic Advances in Chronic Disease</i> , 2022, 13, 204062232210973.	2.5	2
224	The clinical features, image findings and risk factors of vena cava syndrome in Behçet's syndrome. <i>Clinical and Experimental Rheumatology</i> , 0, , .	0.8	2
225	Response to letter "Clinical characteristics and survival of pulmonary arterial hypertension associated with three major connective tissue diseases: Methodological issues" <i>International Journal of Cardiology</i> , 2017, 249, 418.	1.7	1
226	The octopus on a heart. <i>European Heart Journal</i> , 2019, 40, 635-635.	2.2	1
227	Pulmonary inflammatory myofibroblastic tumour and IgG ₄ -related disease presenting with lower limb paralysis. <i>Thorax</i> , 2019, 74, 313-314.	5.6	1
228	Efficacy and safety of ambrisentan in Chinese patients with connective tissue disease-pulmonary arterial hypertension: a post-hoc analysis. <i>BMC Cardiovascular Disorders</i> , 2020, 20, 339.	1.7	1
229	Risk and prognosis factors for systemic sclerosis with lung cancer: A single-centre case-control study in China. <i>International Journal of Clinical Practice</i> , 2021, 75, e13819.	1.7	1
230	Early Initiation of Anticoagulation Improves the Long-Term Prognosis in Patients With Antiphospholipid Syndrome Associated Portal Vein Thrombosis. <i>Frontiers in Medicine</i> , 2021, 8, 630660.	2.6	1
231	Modeling and Simulation to Support Phase Ib/Ila Dose Selection for WBP216, A Long Half-Life Fully Human Monoclonal Antibody Against Interleukin-6. <i>Frontiers in Pharmacology</i> , 2021, 12, 617265.	3.5	1
232	Immunoglobulin G4-Related Disease Accompanied by Primary Myelofibrosis: Case Report. <i>Frontiers in Medicine</i> , 2021, 8, 638794.	2.6	1
233	Quality of life in ambulatory pulmonary arterial hypertension in connective tissue diseases and its relationship with risk stratification. <i>Pulmonary Circulation</i> , 2021, 11, 1-8.	1.7	1
234	Chinese SLE Treatment and Research Group Registry (CSTAR) XIII: prevalence and risk factors for chronic scarring alopecia in patients with systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2021, 23, 20.	3.5	1

#	ARTICLE	IF	CITATIONS
235	Thrombocytopenia Is an Independent Risk Factor for the Prognosis of Thrombotic Microangiopathy in Chinese Patients With Systemic Lupus Erythematosus. <i>Frontiers in Medicine</i> , 2021, 8, 772607.	2.6	1
236	Relapse rates and risk factors for unfavorable neurological prognosis of transverse myelitis in systemic lupus erythematosus: A systematic review and meta-analysis. <i>Autoimmunity Reviews</i> , 2021, 21, 102996.	5.8	1
237	Preoperative immunosuppressive therapy reduces paravalvular leakage after aortic valve surgery in patients with aortic regurgitation attributable to Behçet's disease. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, S26-S33.	0.8	1
238	Chinese lupus treatment and research group (CSTAR) registry: X. family history in relation to lupus clinical and immunological manifestations. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 81-87.	0.8	1
239	Periodic fever, aphthous stomatitis, pharyngitis and cervical adenitis in Chinese adult patients. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 121, 116-118.	0.8	1
240	Clinical characteristics of axial spondyloarthritis patients in China: results from ChinaSpA, the Chinese Spondyloarthritis Registry. <i>Clinical and Experimental Rheumatology</i> , 2021, , .	0.8	1
241	Management of rheumatoid arthritis in China: a study of the implementation of 2019 EULAR recommendations. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1052-1054.	0.9	1
242	Research progress of BK virus and systemic lupus erythematosus. <i>Lupus</i> , 2022, 31, 522-531.	1.6	1
243	Effects of conventional rehabilitative and aerobic training in patients with idiopathic inflammatory myopathy. <i>Rheumatology and Immunology Research</i> , 2022, 3, 23-30.	0.8	1
244	Structural and Functional Characterization of Gray Matter Alterations in Female Patients With Neuropsychiatric Systemic Lupus. <i>Frontiers in Neuroscience</i> , 2022, 16, 839194.	2.8	1
245	Clinical characteristics and outcomes of lupus myocarditis: a retrospective case control study in Chinese patients. <i>Clinical and Experimental Rheumatology</i> , 2022, , .	0.8	1
246	Efficacy of lumiracoxib in relieving pain associated with knee osteoarthritis: a 6-week, randomized, double-blind, parallel-group study. <i>APLAR Journal of Rheumatology</i> , 2007, 10, 190-197.	0.2	0
247	SAT0251â€¦SEX- AND AGE-RELATED DIFFERENCES IN CLINICAL MANIFESTATIONS OF BEHÇET'S DISEASE IN A LARGE COHORT OF CHINA PATIENTS. , 2019, , .		0
248	OP0062â€¦IDENTIFICATION OF SIX DERMATOMYOSITIS SUBGROUPS USING PRINCIPAL COMPONENT ANALYSIS-BASED CLUSTER ANALYSIS. , 2019, , .		0
249	Risk factors for progression of carotid intima-media thickness in patients with systemic lupus erythematosus: protocol for an observational cohort study in China. <i>BMJ Open</i> , 2019, 9, e030721.	1.9	0
250	P191â€¦Chinese systemic lupus erythematosus treatment and research group (CSTAR) registry â€œ subjective well-being in patients with systemic lupus erythematosus. , 2020, , .		0
251	P157â€¦Update on the real-time collecting system data of SLE treatment and research group (CSTAR) registry: clinical features and remission of patients with systemic lupus erythematosus in China. , 2020, , .		0
252	O27â€¦Development and validation of a multivariable model for 5-year survival in systemic lupus erythematosus-associated pulmonary arterial hypertension: CSTAR-PAH cohort study. , 2020, , .		0

#	ARTICLE	IF	CITATIONS
253	2020 Chinese expert-based consensus on the diagnosis and treatment of connective tissue disease associated pulmonary arterial hypertension. <i>Rheumatology and Immunology Research</i> , 2021, 2, 63-78.	0.8	0
254	Comparison of pathological findings between patients with relapsed and non-relapsed immunoglobulin G4-related disease. <i>Chinese Medical Journal</i> , 2021, Publish Ahead of Print, .	2.3	0
255	Vision loss, multiple cerebral infarction, ischemia of extremities: Systemic vasculitis or cardiac myxoma?. <i>Rheumatology and Immunology Research</i> , 2020, 1, 53-55.	0.8	0
256	The history of development of rheumatology in China: From a single center to the whole country. <i>Rheumatology and Immunology Research</i> , 2020, 1, 59-61.	0.8	0
257	Survival and prognostic factors of lung cancer patients with preexisting connective tissue disease: a retrospective cohort study. <i>Annals of Translational Medicine</i> , 2020, 8, 1415.	1.7	0
258	Identification of novel classes for patients with lupus nephritis using two-step cluster model. <i>Wiener Klinische Wochenschrift</i> , 2022, 134, 202-207.	1.9	0
259	Comparative assessment of pharmacokinetic parameters between HS016, an adalimumab biosimilar, and adalimumab (Humira®) in healthy subjects and ankylosing spondylitis patients: Population pharmacokinetic modeling. <i>Advances in Clinical and Experimental Medicine</i> , 2022, 31, 0-0.	1.4	0
260	Study on the association of serum pentraxin-3 and lysosomal-associated membrane protein-2 levels with disease activity in Chinese Takayasu's arteritis patients. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 117, 109-115.	0.8	0
261	Behçet's disease and subacute thyroiditis after a rabies inoculation: a case report and review of the literature. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 127, 126.	0.8	0
262	The modulatory roles of T cell glycosylation in systemic lupus erythematosus. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 889-898.	0.8	0
263	The association of different serum IgG4 levels with distinct clinical characteristics and treatment efficacy in patients with IgG4-related disease. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 727-735.	0.8	0
264	A 16-year-old boy with arthritis, rash, and hemoptysis: Beyond "undifferentiated connective tissue disease". <i>Rheumatology and Immunology Research</i> , 2022, 3, 46-50.	0.8	0
265	Review of Novel Therapies and Update for Takayasu Arteritis and ANCA-Associated Vasculitis with Relevance to the Asia Pacific Region. <i>Journal of Clinical Rheumatology and Immunology</i> , 0, , 1-7.	0.4	0